Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Shah on the Utility of MRD in Frontline Multiple Myeloma

January 13th 2020

Nina Shah, MD, discusses the utility of minimal residual disease in frontline multiple myeloma.

Dr. Lonial on the ICARIA-MM Trial in Heavily Pretreated Multiple Myeloma

January 10th 2020

Sagar Lonial, MD, FACP, discusses the ICARIA-MM trial in patients with multiple myeloma who experience early relapse, have been heavily pretreated, or have refractory disease.

Dr. Chaudhry on Unmet Needs in Relapsed/Refractory Multiple Myeloma

January 9th 2020

Maria Chaudhry, MBBS, discusses unmet needs in relapsed/refractory multiple myeloma.

Expert Highlights Research Developments Across the Spectrum in Multiple Myeloma

January 7th 2020

Maria Chaudhry, MBBS, discusses recent and ongoing research in newly diagnosed and relapsed/refractory multiple myeloma.

Dr. Chaudhry on DRd Triplet in Transplant-Ineligible Multiple Myeloma

January 7th 2020

Maria Chaudhry, MBBS, discusses the use of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone in transplant-ineligible patients with multiple myeloma.

Dr. Martin on Subcutaneous Administration of Daratumumab in Multiple Myeloma

January 3rd 2020

Thomas G. Martin, MD, discusses the impact of subcutaneous administration of daratumumab on patients with early relapse multiple myeloma.

Daratumumab-Based 4-Drug Induction Regimens Improve Outcomes in Myeloma

December 23rd 2019

Ajay K. Nooka, MD, MPH, FACP, discusses the shift in induction regimens in multiple myeloma and the impact of daratumumab (Darzalex) on the space.

FDA Approval Sought for Belantamab Mafodotin in Relapsed/Refractory Myeloma

December 17th 2019

A biologics license application has been filed with the FDA for belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.

Novel Agents and Combos Continue to Transform Myeloma Paradigm

December 17th 2019

Agne Paner, MD, discusses the treatment paradigm in multiple myeloma and promising agents on the horizon.

Dr. Richardson on Preliminary Data With Belantamab Mafodotin in Multiple Myeloma

December 12th 2019

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine at Harvard Medical School, discusses the preliminary data that has been reported with belantamab mafodotin (GSK2857916) in multiple myeloma.

Large PFS Gain With Daratumumab in Transplant-Ineligible Myeloma

December 11th 2019

More than three times as many patients with transplant-ineligible newly diagnosed multiple myeloma remained alive and progression free after >3 years when they received daratumumab (Darzalex) in addition to standard first-line therapy.

Updated bb21217 Data Continue to Impress in Multiple Myeloma

December 11th 2019

The CAR T cell therapy bb21217 demonstrated high very good partial response or better rates in patients with heavily pretreated relapsed/refractory multiple myeloma.

Daratumumab Boosts Outcomes in Transplant-Eligible Myeloma

December 10th 2019

Adding an anti-CD38 antibody to a 3-drug chemotherapy-free regimen led to deeper and more frequent responses in patients with transplant-eligible, newly diagnosed multiple myeloma.

Daratumumab Plus Carfilzomib and Dexamethasone Extends PFS in Relapsed/Refractory Myeloma

December 10th 2019

Adding daratumumab (Darzalex) to carfilzomib (Kyprolis) and dexamethasone reduced the risk of disease progression or death by 37% compared with carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Dr. Biran on 2-Year Update of Immunotherapy Triplet in High-Risk Multiple Myeloma

December 8th 2019

Noa Biran, MD, physician, John Theurer Cancer Center, discusses the 2-year update of a phase II trial of pembrolizumab (Keytruda), lenalidomide (Revlimid), and dexamethasone as post-autologous stem cell transplant consolidation in patients with high-risk multiple myeloma.

Anti-BCMA CAR-T JNJ-4528 Hits 100% Response Rate in Heavily Pretreated Myeloma

December 8th 2019

The BCMA-directed CAR T-cell therapy JNJ-4528 achieved a 100% overall response rate with early and deep responses in 29 patients with heavily pretreated relapsed/refractory myeloma.

Extramedullary Multiple Myeloma Responds to Dual-Targeting CAR T-Cell Therapy

December 7th 2019

Chimeric antigen receptor T-cell therapy targeting both BCMA and CD38 induced an objective response in >90% of patients with multiple myeloma who had been treated with at least 3 prior therapies and whose disease had spread outside of the bone marrow.

Anti-BCMA, CD3 Agent CC-93269 Shows Promise for Heavily Pretreated Myeloma

December 7th 2019

CC-93269 showed encouraging signs of dose-dependent efficacy with a safety profile that continues to be refined for patients with heavily pretreated relapsed/refractory multiple myeloma.

Idecabtagene Vicleucel Meets ORR Endpoint in Relapsed/Refractory Multiple Myeloma

December 7th 2019

Treatment with the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel was associated with a 73.4% overall response rate in patients with relapsed/refractory multiple myeloma, meeting the primary endpoint of the pivotal phase II KarMMA trial.

Landgren Previews Pivotal ASH 2019 Myeloma Data

December 6th 2019

Ahead of the 2019 ASH Annual Meeting, C. Ola Landgren, MD, PhD, shares insight on the potentially practice-changing data in the multiple myeloma paradigm that will be discussed at the conference.